Intradialytic hypertension and its association with endothelial cell dysfunction.

UT Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-8523, USA.
Clinical Journal of the American Society of Nephrology (Impact Factor: 5.07). 08/2011; 6(8):2016-24. DOI: 10.2215/CJN.11351210
Source: PubMed

ABSTRACT Intradialytic hypertension is associated with adverse outcomes, yet the mechanism is uncertain. Patients with intradialytic hypertension exhibit imbalances in endothelial-derived vasoregulators nitric oxide and endothelin-1, indirectly suggesting endothelial cell dysfunction. We hypothesized that intradialytic hypertension is associated in vivo with endothelial cell dysfunction, a novel predictor of adverse cardiovascular outcomes.
We performed a case-control cohort study including 25 hemodialysis (HD) subjects without (controls) and 25 with intradialytic hypertension (an increase in systolic BP pre- to postdialysis ≥10 mmHg ≥4/6 consecutive HD sessions). The primary outcome was peripheral blood endothelial progenitor cells (EPCs) assessed by aldehyde dehydrogenase activity (ALDH(br)) and cell surface marker expression (CD34(+)CD133(+)). We also assessed endothelial function by ultrasonographic measurement of brachial artery flow-mediated vasodilation (FMD) normalized for shear stress. Parametric and nonparametric t tests were used to compare EPCs, FMD, and BP.
Baseline characteristics and comorbidities were similar between groups. Compared with controls, 2-week average predialysis systolic BP was lower among subjects with intradialytic hypertension (144.0 versus 155.5 mmHg), but postdialysis systolic BP was significantly higher (159.0 versus 128.1 mmHg). Endothelial cell function was impaired among subjects with intradialytic hypertension as measured by decreased median ALDH(br) cells and decreased CD34(+)CD133(+) cells (ALDH(br), 0.034% versus 0.053%; CD34(+)CD133(+), 0.033% versus 0.059%). FMD was lower among subjects with intradialytic hypertension (1.03% versus 1.67%).
Intradialytic hypertension is associated with endothelial cell dysfunction. We propose that endothelial cell dysfunction may partially explain the higher event rates observed in these patients.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The field of uremic toxicity comprises the study of a large number of different substances, classified in relation to various characteristics, for example protein-binding, dimensions, etc. The endogenous compounds of gaseous nature have lately received much attention from the scientific community, because of their increasingly recognized importance in health and disease. Among these substances, some are uremic toxins per se, others are related to uremic toxins, or can become toxic under some circumstances. We divided them into two broad categories: organic and inorganic compounds. Among the organic compounds, we find phenols, indols, 2-methoxyresorcinol, p-hydroxy hippuric acid, and phenyl acetic acid, trimethylamine and dimethylamine; among the inorganic solutes, ammonia, nitric oxide, carbon monoxide, and hydrogen sulfide. In this chapter, these substances are described in relation to the elements that they affect or by which they are affected in uremia, which are the blood, breath, stools and the gastrointestinal tract, and this in general and during the dialysis procedure.
    Seminars in Nephrology 03/2014; · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Park et al. performed a retrospective analysis of a large hemodialysis cohort to describe the relationship between pre- to postdialysis changes in BP and mortality. Their study demonstrated adverse outcomes associated both with large decreases and with any increase in blood pressure pre- to postdialysis. Although limitations exist in this analysis, which lacked intradialytic blood pressure measurements, the results support the ongoing concern about the potential adverse hemodynamic stress associated with conventional three-times-weekly hemodialysis.
    Kidney International 10/2013; 84(4):641-644. · 8.52 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background and Objectives: Erythropoiesis-stimulating agents (ESAs) might moderate circu-lating CD34-positive hematopoietic stem (CD34 +) cells. We assessed associations between ESA therapy and CD34 + cells and their impact on cardiovascular disease (CVD) events in patients on prevalent hemodialysis (HD). Design, Setting, Participants and Measurements: We analyzed 95 patients on prevalent HD who received the ESAs epoetin-(n = 22), darbepoetin-(n = 60), or neither (control; no ESA, n = 13). Baseline values for CD34 + cells, high-sensitivity C-reactive protein, interleukin-6, vascular endothelial growth factor, inter-cellular adhesion molecule-1, and carotid intima-media thickness were determined. The numbers of CD34 + /erythropoietin receptor (EPOR) + cells were determined in 35 and 8 patients in the darbepoetin-and control groups, respectively. CD34 + cells were counted after 6 and 12 months of darbepoetin-treat-ment (n = 35). All patients were followed up for a mean of 28 months. Results: Hemoglobin levels were lower, carotid intima-media thickness was more pronounced, and the ESA dose was higher in patients with a low, than with a high, CD34 + cell count. The ratio of CD34 + /EPOR + to CD34 + cells positively correlated with the darbepoetin-dose. A low, but not a high, dose of darbepoetin-for 6 and 12 months was associated with more CD34 + cells. Although high-dose darbepoetin-therapy was an independent predictor of composite CVD events, this associa-tion disappeared when adjusted for the CD34 + cell count with other confounders. Conclusions: High-dose ESA therapy is associated with a low CD34 + cell count and comprises a risk factor for CVD events in patients on prevalent HD.